ROCKVILLE, Md., Dec. 19, 2016 /PRNewswire/ -- The use of cell-free DNA (cfDNA) and "liquid biopsies" of other analytes has received a huge amount of attention in recent years, due to its potential to make diagnosis and treatment of several conditions non-invasive, according to Kalorama Information. The healthcare market research firm said this has translated into a $170 million-dollar market cfDNA instruments, consumables, and software. Kalorama Information said the market for cfDNA was The finding was made in Kalorama Information report, Cell-Free DNA (cfDNA) Markets (report: http://www.kaloramainformation.com/Cell-Free-DNA-10494559/).
cfDNA is DNA detectable in circulating blood. Medical literature suggests cell-free DNA in plasma or serum has the clinical potential to be a more specific tumor marker for the diagnosis and prognosis, as well as the early detection, of cancer. Agilent, Roche, Fluidigm, Illumina, Qiagen, Thermo Fisher Scientific are among the companies with products in the market.
"Prenatal has become the largest diagnostic segment of cfDNA analysis, but oncology is the area that is expected to demonstrate the technology's effectiveness and enlarge the market for instruments and consumables," said Bruce Carlson, Publisher of Kalorama Information. "Though it's still unknown regarding how successful it will be, and how rapidly it will occur. Given the increasing rates of cancer and the difficulty in its treatment, there could be a huge impact."
The report notes that the detection of aneuploidies and other genetic disorders with primarily next-generation sequencing (NGS) has been a paradigm shift. The adoption has been progressing from high-risk to average-risk pregnancies. Previously, the invasive procedures such as amniocentesis could bring a 1 in 300 chance of miscarriage. The tests have been continuously improved and it is possible they will be expanded to a range of genetic diseases. There has been promising research related to cardiovascular (stroke, heart attack) uses, inflammation, autoimmune diseases, infection (sepsis, etc), trauma/ injury, and neurodegenerative diseases. Some of this has also included circulating tumor cells (CTCs), exosomes, and other extracellular vesicles (EVs), which are not the focus of this report but which are included in many sections and which face similar dynamics.
According to the report there is a variety of possible clinical uses of liquid biopsies in oncology, including early detection, identification of mutations/ genetic determinants for targeted therapy ; patient stratification and therapy selection; companion diagnostics, monitoring of minimal residual disease, profiling of molecular heterogeneity of overall disease, monitoring of tumor dynamics, metastases, disease prognosis and other areas. Genes being analyzed by the current products for cfDNA analysis primarily include the following: BRAF, EGFR, ESR1, KRAS, MET, PIK3CA, TP53, KIT and PDGFRA.
This Kalorama Information report, Cell-Free DNA (cfDNA) Markets, is designed to address that need. The report focuses on the market for cfDNA analysis instruments, consumables, kits, and related software, which includes the sample preparation products and equipment as well as the next generation sequencing (NGS) and digital polymerase chain reaction (dPCR) systems used for detection. The report provides complete market information, including current market estimates and forecasts to 2021.
Please link any media or news references to our reports or data to http://www.kaloramainformation.com/.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.
We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog on our company website.
212 807 2262
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/promise-of-liquid-biopsy-driving-cell-free-dna-markets-report-300381383.html
SOURCE Kalorama Information